The path of transcatheter aortic valve implantation: from compassionate to low-risk cases

Abstract Aortic stenosis (AS) is one of the most common valvular diseases in developed countries. Transcatheter aortic valve implantation (TAVI) has emerged as alternative to medical treatment or surgical aortic valve replacement (SAVR) in all symptomatic patients with severe AS. In 2002, Cribier performed the first human TAVI through a trans-septal approach in a 57-year-old man with severe AS. Since then, several trials have compared TAVI vs. SAVR over the years. Today, it is superior in terms of mortality to medical therapy in extreme-risk patients, non-inferior or superior to surgery in high-risk patients, and non-inferior to surgery and even superior when transfemoral access is possible in intermediate-risk patients. Interesting results emerged from the latest multicentre trials involving patients with severe AS who were at low risk for death from surgery, demonstrating that this therapy will be offered to younger people in the next future.

[1]  J. Leipsic,et al.  Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[2]  Andrew S. Mugglin,et al.  Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[3]  D. Capodanno,et al.  Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. , 2019, Journal of the American College of Cardiology.

[4]  D. Adams,et al.  5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. , 2018, Journal of the American College of Cardiology.

[5]  A. Yoganathan,et al.  Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. , 2018, Circulation.

[6]  C. Tamburino,et al.  Percutaneous Treatment of Left Side Cardiac Valves , 2018, Springer International Publishing.

[7]  D. Adams,et al.  5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. , 2018, Journal of the American College of Cardiology.

[8]  B. Prendergast,et al.  Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Societ , 2017, European heart journal.

[9]  Andrew S. Mugglin,et al.  Surgical or Transcatheter Aortic‐Valve Replacement in Intermediate‐Risk Patients , 2017, The New England journal of medicine.

[10]  Jeroen J. Bax,et al.  Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Societ , 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  M. Mack,et al.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.

[12]  M. Mack,et al.  5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial , 2015, The Lancet.

[13]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[14]  S. Pocock,et al.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.